Immunogen, Inc.
IMGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.73B
Close$
$33.47
7.1% upside
Current Fair Value
7.1% upsideUndervalued by 7.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.73 Billion |
|---|---|
| Enterprise Value | $8.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.88 |
| Beta | 1.17 |
| Outstanding Shares | 273,341,000 |
Return
| Return on Equity | -13.01% |
|---|---|
| Return on Assets | -8.89% |
| Return on Invested Capital | -11.45% |
Valuation & Multiples
| P/E Ratio | -35.54 |
|---|---|
| PEG | 25.47 |
| Price to Sales | 31.24 |
| Price to Book Ratio | 15.62 |
| Enterprise Value to Revenue | 28.53 |
| Enterprise Value to EBIT | -104.23 |
| Enterprise Value to Net Income | -113 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Immunogen, Inc.
CEO: Mark Enyedy